Figure 4

Performance evaluation of the LncSig in the testing and whole set. Kaplan–Meier estimates of overall survival of patients with low or high risk predicted by the LncSig in the testing set (A) and whole set (B). Time-dependent ROC curves analysis of the LncSig at 3 years in the testing set (C) and whole set (D). LncRNA expression patterns and the distribution of somatic mutation count distribution and KRAS expression for patients in high- and low-risk groups in the testing set (E) and whole set (F). The distribution of somatic mutation and KRAS expression in patients of high- and low-risk groups in the testing set (G) and whole set (H).